Treglia Giorgio, Taralli Silvia, Bertagna Francesco, Salsano Marco, Muoio Barbara, Novellis Pierluigi, Vita Maria Letizia, Maggi Fabio, Giordano Alessandro
Institute of Nuclear Medicine, Catholic University of the Sacred Heart, 00168 Rome, Italy.
Radiol Res Pract. 2012;2012:431029. doi: 10.1155/2012/431029. Epub 2012 Sep 9.
Aim. To systematically review the role of positron emission tomography (PET) with fluorine-18-fluorodeoxyglucose (FDG) in patients with neurofibromatosis type 1 (NF1). Methods. A comprehensive literature search of published studies regarding FDG-PET and PET/CT in patients with NF1 was performed. No beginning date limit and language restriction were used; the search was updated until December 2011. Only those studies or subsets in studies including whole-body FDG-PET or PET/CT scans performed in patients with NF1 were included. Results. We identified 12 studies including 352 NF1 patients. Qualitative evaluation was performed in about half of the studies and semiquantitative analysis, mainly based on different values of SUV cutoff, in the others. Most of the studies evaluated the role of FDG-PET for differentiating benign from malignant peripheral nerve sheath tumors (MPNSTs). Malignant lesions were detected with a sensitivity ranging between 100% and 89%, but with lower specificity, ranging between 100% and 72%. Moreover, FDG-PET seems to be an important imaging modality for predicting the progression to MPNST and the outcome in patients with MPNST. Two studies evaluated the role of FDG-PET in pediatric patients with NF1. Conclusions. FDG-PET and PET/CT are useful methods to identify malignant change in neurogenic tumors in NF1 and to discriminate malignant from benign neurogenic lesions.
目的。系统评价18F-氟脱氧葡萄糖（FDG）正电子发射断层扫描（PET）在1型神经纤维瘤病（NF1）患者中的作用。方法。对已发表的关于FDG-PET和PET/CT在NF1患者中的研究进行全面文献检索。未设置起始日期限制和语言限制；检索更新至2011年12月。仅纳入那些在NF1患者中进行全身FDG-PET或PET/CT扫描的研究或研究子集。结果。我们确定了12项研究，包括352例NF1患者。约一半的研究进行了定性评估，其他研究则主要基于不同的SUV临界值进行半定量分析。大多数研究评估了FDG-PET在鉴别良性与恶性周围神经鞘瘤（MPNST）中的作用。检测恶性病变的灵敏度在100%至89%之间，但特异性较低，在100%至72%之间。此外，FDG-PET似乎是预测NF1患者进展为MPNST以及MPNST患者预后的重要影像学检查方法。两项研究评估了FDG-PET在NF1儿科患者中的作用。结论。FDG-PET和PET/CT是识别NF1患者神经源性肿瘤恶性变化以及区分恶性与良性神经源性病变的有用方法。
